Treatment of cardiac manifestations in Fabry disease with the oral drug Migalastat: First 12 months results from a cohort of amenable all-comers

Back

ESC Premium Access

Treatment of cardiac manifestations in Fabry disease with the oral drug Migalastat: First 12 months results from a cohort of amenable all-comers

Session: Cardiomyopathy in Fabry disease

Topic: Infiltrative Myocardial Disease

Speaker: Doctor J. Muentze (Wuerzburg, DE)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Jonas Muentze

University Hospital Wuerzburg, Wuerzburg (Germany)

0 follower

5 more presentations in this session

Hypertrophy of unaffected cardiomyocytes concurs to severity of cardiomyopathy in female patients with Fabry disease

Speaker: Associate Professor C. Chimenti (Rome, IT)

Access

Abstract

Plasma lysoGb3 useful as biomarker in screening for Fabry disease in patients with mild left ventricular hypertrophy

Speaker: Doctor M. Kagimoto (Yokohama, JP)

Speckle-tracking analysis of right ventricular function in Fabry disease - is left ventricle the only diseased chamber ?

Speaker: Doctor J. Liao (Taipei, TW)

Access

Abstract

Cardiac magnetic resonance imaging in Fabry cardiomyopathy

Speaker: Professor S. Moiseev (Moscow, RU)

Novel electrocardiographic parameters for the detection of Fabry Disease - A comparative multi-centre study

Speaker: Doctor M. Namdar (Geneva, CH)

Access the full session

Cardiomyopathy in Fabry disease

Speakers: Doctor J. Muentze, Associate Professor C. Chimenti, Doctor M. Kagimoto, Doctor J. Liao, Professor S. Moiseev...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources